Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC
Blood tests can now identify which lung cancer patients benefit most from a specific targeted drug, guiding personalized treatment decisions.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Whole-genome sequencing of cell-free DNA for assessment of minimal…
A simple blood test using whole-genome sequencing detects early myeloma without bone marrow biopsy, enabling closer monitoring of high-risk patients.
SR/MA validates AI prognostics in AML; CBC/ML drought brokenArtificial intelligence-based prognostic models in acute myeloid leukemia
AI-based prognostic tools for acute myeloid leukemia now match or exceed standard clinical assessments, offering doctors a powerful new decision-support option.
CBC-ML cardiovascular risk, two-cohort validationHematologic biomarkers of aging (HemeAge) and cardiovascular risk
Standard blood count data combined with machine learning can now flag cardiovascular risk without extra testing, making risk assessment faster and more accessible.
SGLT-2 HFpEF SR/MA of RCTsImpact of SGLT-2 inhibitors on long-term prognosis in patients with…
SGLT-2 inhibitors significantly reduce deaths and hospitalizations in heart failure patients with preserved function, a condition long lacking proven treatments.